Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept autoinjector vs lyophilized formulation in healthy females
NCT06930664Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotatercept (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity at 120 days, Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration at 120 days and 1 more. Started May 2025; status: completed.
02
Drugs
sotatercept
Beyond the preview
Go deeper on NCT06930664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930664.